Jun 26, 2026 08:45AM
May 28, 2026 09:10AM
May 28, 2026 09:10AM
May 22, 2026 07:00AM
May 19, 2026 07:00AM
May 19, 2026 07:00AM
May 13, 2026 04:01PM Medicenna launches public offering to fund clinical programs
May 13, 2026 04:01PM
May 12, 2026 07:00AM
Apr 30, 2026 07:30AM
Apr 21, 2026 07:30AM
Apr 14, 2026 07:30AM
Feb 13, 2026 08:09AM
Dec 9, 2025 05:04PM Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
Nov 13, 2025 07:00AM
Oct 23, 2025 05:12PM
Oct 1, 2025 09:35AM
Apr 22, 2025 07:00AM
Apr 1, 2025 07:00AM
Mar 26, 2025 07:00AM
Feb 25, 2025 07:05AM Medicenna Therapeutics (MDNA) Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells
Feb 25, 2025 07:00AM
Feb 13, 2025 10:28AM
Feb 5, 2025 07:00AM
Dec 13, 2024 08:30AM
Dec 5, 2024 07:35AM
Nov 27, 2024 07:02AM
Nov 27, 2024 07:00AM Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
Nov 25, 2024 07:30AM
Nov 15, 2024 07:30AM
Nov 13, 2024 07:00AM
Nov 11, 2024 07:00AM
Nov 8, 2024 10:00AM
Oct 4, 2024 09:07AM
Sep 26, 2024 05:00PM Medicenna Announces Results of Annual Meeting of Shareholders
Sep 9, 2024 07:32AM
Sep 5, 2024 07:00AM
Aug 27, 2024 07:00AM
Aug 15, 2024 07:31AM
Aug 15, 2024 07:30AM
Aug 1, 2024 07:00AM
Jun 27, 2024 08:18AM Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
Jun 26, 2024 07:47AM
Jun 3, 2024 08:00AM
May 31, 2024 09:29AM
May 22, 2024 07:00AM
May 13, 2024 07:00AM
Apr 24, 2024 10:05AM
Apr 10, 2024 06:32AM Medicenna Therapeutics (MDNA) Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Apr 10, 2024 06:30AM

325,447 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All